摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-溴-6-氯烟酸甲酯 | 78686-77-8

中文名称
5-溴-6-氯烟酸甲酯
中文别名
——
英文名称
methyl 5-bromo-6-chloronicotinate
英文别名
methyl 5-bromo-6-chloropyridine-3-carboxylate
5-溴-6-氯烟酸甲酯化学式
CAS
78686-77-8
化学式
C7H5BrClNO2
mdl
——
分子量
250.479
InChiKey
WINGWVOUOFMOJQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    75-77°C
  • 沸点:
    279.2±35.0 °C(Predicted)
  • 密度:
    1.684
  • 溶解度:
    氯仿(微溶)、甲醇(微溶)、水(微溶)

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    39.2
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 危险类别码:
    R22
  • 海关编码:
    2933399090
  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H302
  • 储存条件:
    2~8℃

SDS

SDS:2e1213aaf4afefcf1228f90314505531
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Methyl 5-bromo-6-chloronicotinate
Synonyms: Methyl 3-bromo-2-chloropyridine-5-carboxylate

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 5-bromo-6-chloronicotinate
CAS number: 78686-77-8

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5BrClNO2
Molecular weight: 250.5

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    [EN] PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS
    [FR] COMPOSÉS DE PYRIDONE SUBSTITUÉE PAR PYRAZOLYL EN TANT QU'INHIBITEURS DE SÉRINE PROTÉASE
    摘要:
    其中提供了一些取代吡唑基吡啶酮化合物,这些化合物表现出生物活性,例如对丝氨酸蛋白酶(包括凝血酶和各种激肽酶)的抑制作用。此外还提供了药物组合物。此外还提供了治疗和预防某些疾病或疾病的方法,该疾病或疾病可通过抑制丝氨酸蛋白酶(包括凝血酶和各种激肽酶)来治疗或预防。
    公开号:
    WO2016044662A1
  • 作为产物:
    描述:
    参考文献:
    名称:
    3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents
    摘要:
    本发明涉及一种提高HDL胆固醇的方法,包括向需要的患者施用以下公式的化合物: 其中A、G、R1至R8和R17如描述中所定义。
    公开号:
    US20080085906A1
点击查看最新优质反应信息

文献信息

  • [EN] BICYCLIC HYDROXAMIC ACIDS USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY<br/>[FR] ACIDES HYDROXAMIQUES BICYCLIQUES UTILES COMME INHIBITEURS DE L'ACTIVITÉ HISTONE DÉSACÉTYLASE CHEZ LE MAMMIFÈRE
    申请人:KANCERA AB
    公开号:WO2017108282A1
    公开(公告)日:2017-06-29
    A compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of a histone deacetylase, and as such is useful in terepy, e.g. in the treatment of autoimmune disorders, mental disorders, neurodegenerative disorders, and hyperproliferative disorders.
    化合物的化学式(Ia)或(Ib)或其药学上可接受的盐。该化合物是组蛋白去乙酰化酶抑制剂,因此在治疗自身免疫性疾病、精神障碍、神经退行性疾病和过度增生性疾病等方面非常有用。
  • [EN] N-(HETEROCYCLYL AND HETEROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE DERIVATIVES AS SSTR4 AGONISTS<br/>[FR] DÉRIVÉS DE N-(HÉTÉROCYCLYL ET HÉTÉROCYCLYLALKYL)-3-BENZYLPYRIDIN-2-AMINE SERVANT D'AGONISTES DE SSTR4
    申请人:TAKEDA PHARMACEUTICALS CO
    公开号:WO2021202775A1
    公开(公告)日:2021-10-07
    Disclosed are compounds of Formula (1), and pharmaceutically acceptable salts thereof, wherein n, R1, R4, R5, R6, R7, R8, R9, R10, R11, R14, X2, X3 and X12 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.
    披露了公式(1)的化合物,以及其中n、R1、R4、R5、R6、R7、R8、R9、R10、R11、R14、X2、X3和X12在说明书中定义的药用可接受盐。本公开还涉及用于制备公式(1)化合物的材料和方法,含有它们的药物组合物,以及它们用于治疗与SSTR4相关的疾病、障碍和状况。
  • [EN] IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS<br/>[FR] COMPOSÉS D'IMIDAZOPYRIDINE ET D'IMIDAZOPYRAZINE UTILISÉS COMME INHIBITEURS DE KINASE
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2009155388A1
    公开(公告)日:2009-12-23
    A compound of Formula (I) or Formula (II) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) or Formula (II), and methods of treating conditions associated with the activity of p38 kinase.
    一种由化合物(I)或化合物(II)及其对映体、二对映体和药学上可接受的盐组成的复合物。还公开了含有化合物(I)或化合物(II)的药物组合物,以及治疗与p38激酶活性相关疾病的方法。
  • [EN] BROMODOMAIN INHIBITORS<br/>[FR] INHIBITEURS DE BROMODOMAINE
    申请人:ABBVIE INC
    公开号:WO2018068283A1
    公开(公告)日:2018-04-19
    Provided herein are compounds of formula (I) wherein R 1, Y, L 1, G 1, X 1, X 2, L 2, R 2, R 3, and R 4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, which are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    本文提供了式(I)的化合物,其中R 1、Y、L 1、G 1、X 1、X 2、L 2、R 2、R 3和R 4具有规范中定义的任何值,以及其药学上可接受的盐,这些化合物在治疗疾病和病况中是有用的,包括炎症性疾病、癌症和艾滋病。还提供了包含式(I)化合物的药物组合物。
  • BETA-LACTAMASE INHIBITORS
    申请人:VenatoRx Pharmaceuticals, Inc.
    公开号:US20140194386A1
    公开(公告)日:2014-07-10
    Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    本文描述了调节β-内酰胺酶活性的化合物和组合物。在某些实施例中,所述化合物抑制β-内酰胺酶。在特定实施例中,所述化合物在治疗细菌感染方面是有用的。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-